The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a common subtype of breast cancer. In combination with Pfizer's CDK4/6 inhibitor ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Mature overall survival results of the INAVO120 trial were presented in a press conference for the American Society of ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non ...

There's a new self-guided way to screen for cervical cancer at home that was approved by the FDA. But doctors caution that it ...

The US Food and Drug ... FDA has also granted accelerated approval to AbbVie’s Emrelis for the treatment of previously treated, locally advanced or metastatic non-squamous non–small-cell lung ...